Orkambi Closer to Being Approved in Europe to Treat Children Ages 2-5 With Cystic Fibrosis
cystic fibrosis, News
The European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Orkambi (lumacaftor/ivacaftor) as a treatment for children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, ... Read more